Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 23:14:e14.
doi: 10.15420/usc.2020.13. eCollection 2020.

Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention

Dimitrios Alexopoulos  1 , Charalampos Varlamos  1 , Despoina-Rafailia Benetou  1
Affiliations
Review

Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention

Dimitrios Alexopoulos et al. US Cardiol. .

Abstract

Complex percutaneous coronary intervention (PCI) patients are a high-risk population for ischemic complications. Antiplatelet therapy in such patients remains controversial, as the beneficial effects of the use of more potent agents or prolonged dual antiplatelet treatment (DAPT) on atherothrombotic complications are hindered by a concomitant increase in bleeding rates. The aim of this article is to describe ischemic and bleeding outcomes associated with complex PCI procedures and to compare different types and durations of DAPT regimens in terms of safety and efficacy outcomes. Issues concerning special patient groups, such as those with left main, chronic total occlusion, or bifurcation lesions, are discussed.

Keywords: Complex percutaneous coronary intervention; antiplatelet therapy; bifurcation; chronic total occlusion; dual antiplatelet treatment; left main occlusion.

PubMed Disclaimer

Conflict of interest statement

Disclosure: DA has received lecturing honoraria/advisory board fees from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, Medtronic, Biotronik, and Chiesi Hellas. All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Definition of a Complex PCI Patient
See this image and copyright information in PMC

References

    1. Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European 6. Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60. doi: 10.1093/eurheartj/ehx419. - DOI - PubMed
    1. Généreux P, Giustino G, Redfors B et al. Impact of percutaneous 7. coronary intervention extent, complexity and platelet reactivity on outcomes after drug eluting stent implantation. Int J Cardiol. 2018;268:61–7. doi: 10.1016/j.ijcard.2018.03.103. - DOI - PubMed
    1. Yeh RW, Kereiakes DJ, Steg PG et al. Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention. J Am Coll Cardiol. 2017;70:2213–23. doi: 10.1016/j.jacc.2017.09.011. - DOI - PMC - PubMed
    1. Costa F, Van Klaveren D, Feres F et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019;73:741–54. doi: 10.1016/j.jacc.2018.11.048. - DOI - PubMed
    1. Bortnick AE, Epps KC, Selzer F et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol. 2014;113:573–9. doi: 10.1016/j.amjcard.2013.10.039. - DOI - PMC - PubMed

LinkOut - more resources